Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.880
-0.080 (-4.08%)
Nov 21, 2024, 11:48 AM EST - Market open

Company Description

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers.

The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development.

Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer.

Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings.

The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.

The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Limited
Immutep logo
Country Australia
Founded 1987
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Marc Voigt

Contact Details

Address:
Australia Square, Level 32
Sydney, NSW 2000
Australia
Phone 61 2 8315 7003
Website immutep.com

Stock Details

Ticker Symbol IMMP
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency AUD
CIK Code 0001692528
CUSIP Number 45257L108
ISIN Number US45257L1089

Key Executives

Name Position
Marc Voigt Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer and Executive Director
Deanne Miller LLB Chief Operating Officer, General Counsel and Joint Company Secretary
Dr. Frederic Triebel M.D., Ph.D. Chief Scientific Officer and Executive Director
Dr. Florian D. Vogl M.D., M.Sc., Ph.D. Chief Medical Officer
Christian Mueller BBA, MSc. Senior Vice President of Regulatory and Strategy
Indira Naidu Joint Company Secretary

Latest SEC Filings

Date Type Title
Dec 21, 2020 F-6EF Registration of American Depository Receipt shares, immediately effective
Oct 25, 2019 424B3 Prospectus
Feb 13, 2019 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 28, 2018 SC 13G Statement of acquisition of beneficial ownership by individuals
Dec 4, 2017 424B3 Prospectus
Dec 20, 2016 424B3 Prospectus